Abstract: Biocidal branched quaternary ammonium polymers are made by condensing a difunctional halide with a trifunctional tertiary amine and optionally with a difunctional amine. The branched quaternary ammonium polymers have 2-dimensional conformation that provides better coverage over the surfaces of microorganisms and enhances efficacy as biocides as compared to most commercially available linear (one-dimensional) quaternary ammonium polymers. The bulkier 2-dimensional conformation of this invention limits the uptake, accumulation and release of these branched polymers to and from contact lenses. Therefore, these branched quaternary ammonium polymers can reduce the cytotoxicity, enhance compatibility and suitable for ophthalmic use. The highly branched polymers can be prepared with minimum or no difunctional tertiary amines. The lightly branched polymers can be prepared with of a minimum ratio of trifunctional tertiary amines/difunctional tertiary amines.
Abstract: The invention provides methods, compositions, and dietary formulations useful for preventing or treating dermatitis, promoting healthy skin, and retarding skin aging. The methods comprise administering to an animal a therapeutically effective amount of a combination of at least two of one or more antioxidants; one or more anti-glycation agents; one or more body fat reducing agents; one or more insulin sensitivity enhancing agents; and one or more anti-inflammatory agents.
Type:
Grant
Filed:
October 21, 2011
Date of Patent:
April 5, 2016
Assignee:
Nestec S.A.
Inventors:
Yuanlong Pan, Steven Scott Hannah, Rondo Paul Middleton
Abstract: A dispersion preparation provides transmission attenuation of ultraviolet A and ultraviolet B and ultraviolet C light comprises a dispersion of an effective amount of diamond nanoparticles in a physiologically compatible medium, where the diamond nanoparticles have a size greater than about 60 nm and are modified to enhance absorption of UV radiation. This abstract is not to be considered limiting, since other embodiments may deviate from the features described in this abstract.
Abstract: A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent is added in amounts sufficient to reduce or prevent vasodilation. This treatment method increases or promotes the size of the coagulation zone created after energy-based therapy.
Abstract: Embodiments provided herein relate to compositions, methods, and devices useful for treating eye stain. More particularly, compositions and devices are provided that include tylosin and a carrier suitable for ophthalmic application. Such compositions and devices can be used to treat eye stain in an animal, such as a dog or cat.
Abstract: The present disclosure is directed to peptide-based compounds, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present disclosure may inhibit neurotransmitter release and muscle contraction as a treatment for wrinkles. The compounds of the disclosure may be used for pathological neuronal exocytosis-mediated cosmetic and/or therapeutic purposes.
Type:
Grant
Filed:
November 7, 2012
Date of Patent:
February 2, 2016
Assignee:
GRF (WUHAN) BIOTECHNOLOGY INC.
Inventors:
Feng Tian, Daniel Liang Zou, Lingyun Ji
Abstract: The invention provides a sanitizing composition in the form of a viscous liquid or gel suitable for use as a handwash composition comprising alcohol, water and a thickener wherein the viscous liquid or gel has particles suspended therein, wherein said particles provide the composition with a granular texture and are capable of being worn away when rubbed. The particles may deliver one or more agents to the skin e.g. antimicrobial, antibacterial or antiviral agents, emollients and/or moisturizers, fragrances, colorings or UV markers.
Abstract: Methods of cleansing skin comprise the steps of contacting the skin with a cleansing compositions comprising a fatty ester in combination with a lipid, and either rinsing the composition from the skin with water or wiping the composition from the skin with a dry or damp substrate. The cleansing compositions can comprise at least 8%, by weight of the composition, of fatty ester and/or further comprise a nonionic surfactant and less than about 50%, by weight of the composition, of an alcohol solvent such as ethanol, isopropanol, or mixtures thereof. The methods and compositions provide skin cleansing and hydration benefits.
Type:
Grant
Filed:
September 16, 2013
Date of Patent:
January 19, 2016
Assignee:
The Procter & Gamble Company
Inventors:
Timothy Woodrow Coffindaffer, Mannie Lee Clapp, Dennis Eugene Kuhlman, Kenneth Eugene Kyte, III, Daniel Burton Sears, Barbara Kay Williams
Abstract: This disclosure provides sunscreen products that contain metal oxide powders having discrete size distributions. Metal oxide powders include, for example, zinc oxide and titanium dioxide. Sunscreen products made in accordance with the principles of this disclosure contain metal oxide powders having primary particle sizes of about 10-30 ran and about 50-200 nm.
Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
September 3, 2009
Date of Patent:
December 29, 2015
Assignees:
Pozen Inc., Horizon Pharma USA, Inc.
Inventors:
Brian Ault, Mark Sostek, Everardus Orlemans, John R. Plachetka
Abstract: The present invention provides a highly palatable colon cleansing formulation that utilizes a low chloride electrolyte-replenishing base solution. When formulated with polyethylene glycol and a selected sugar alcohol, the formulation offers the advantages of superior palatability without undesirable concomitant side effects or a decrease in cleansing efficacy.
Abstract: The method for treating traumatic brain injury in an individual includes the step of administering a therapeutically effective amount of a pharmaceutically acceptable gallium compound to a blood brain barrier of the individual within a therapeutically effective time period subsequent to the injury so as to reduce secondary injury in a brain of the individual. Secondary injuries include swelling of the brain after the initial injury, secondary lesions, hematomas, and edema. The effective amount and effective time period for the step of administering are established by test results disclosed in the present invention. Gallium compounds are shown to reduce oxidative stress levels in the brain, a metric for treatment of traumatic brain injury or concussion.
Abstract: A protective coating for covering a biological material, the protective coating having a plurality of interconnected layers covalently bonded to each other. The plurality of interconnected layers can include at least one hyperbranched polymeric material, and at least one dendrimer. A method of forming a protective coating for covering a biological material, the method can include depositing a plurality of interconnected layers, which are covalently bonded to each other. The plurality of interconnected layers can include at least one hyperbranched polymeric material, and at least one dendrimer.
Abstract: Hair treatment compositions are disclosed comprising a ?-amino ester compound in a cosmetically acceptable vehicle, such as a spray or cream. In embodiments, the compounds include a polybutadiene moiety. Methods of treating hair with the compositions to impart volume, texture and definition are also disclosed.
Type:
Grant
Filed:
March 25, 2014
Date of Patent:
November 3, 2015
Assignee:
Living Proof, Inc.
Inventors:
David Thomas Puerta, Susan Alice Thiell, Ronald P. McLaughlin, Daniel Griffith Anderson
Abstract: This document relates to methods and materials for reducing the risk of infection after a shoulder surgery or medical procedure. For example, this document relates to methods and materials for using a topical composition containing clindamycin or erythromycin to reduce the risk of or to prevent infection associated with shoulder surgeries or medical procedures.
Type:
Grant
Filed:
October 24, 2012
Date of Patent:
November 3, 2015
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: A laminated sheet is produced by forming an adhesion layer permeable to a liquid component and contactable with a skin on at least one side of a liquid-retention layer comprising a nonwoven structural member and having an ability to absorb the liquid component. The adhesion layer comprises a nonwoven structural member comprising a fiber having a number-average fiber diameter of not more than 10 ?m, and the thickness ratio of the adhesion layer relative to the liquid-retention layer is 1/4 to 1/100 as a ratio of the adhesion layer/the liquid-retention layer. The fiber of the nonwoven structural member of the adhesion layer may have a standard deviation of fiber diameter of not more than 5. The nonwoven structural member of the liquid-retention layer may comprise a fiber having a fiber diameter larger than that of the fiber of the adhesion layer.
Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
October 27, 2015
Assignee:
Rigel Pharmaceuticals, Inc.
Inventors:
Rajinder Singh, Matthew Duncton, Jing Zhang, Salvador Alvarez, Kin Tso, Sacha Holland, Rose Yen, Rao Kolluri, Thilo Heckrodt, Yan Chen, Esteban Masuda, Hui Li, Donald G. Payan
Abstract: Arbutin-containing compositions are useful for topical application to provide enhanced luminosity, brightening or lightening to the skin of a user and are at least 85% as efficacious (with regard to skin lightening, when used alone or in a system as measured by Chromameter® b* parameter values) as substantially corresponding compositions containing hydroquinone in an amount from about the same molar amount to about 1.5 times the molar amount of arbutin.
Abstract: The invention relates to a product for oral delivery of nicotine containing a core comprising a powder of at least one free nicotine salt, at least one pH adjusting agent and at least one filler, and a water insoluble pouch, wherein said pouch is permeable for saliva and therein dissolved parts of the powder, wherein said product upon contact with purified water gives a pH of at least 6. The invention also relates to a method to manufacture such a product.
Abstract: The present invention generally relates to the transdermal delivery of various compositions. In some aspects, the transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ibuprofen and/or an ibuprofen salt, a nitric oxide donor, and optionally, a hostile biophysical environment. In some cases, the composition may be stabilized using a stabilization polymer such as xanthan gum, KELTROL® BT and/or KELTROL® RD; propylene glycol; and a polysorbate surfactant such as Polysorbate 20, which unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.